-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

TKI-Associated Cardiovascular Toxicity: What to Consider

Program: Education Program
Session: Chronic Myeloid Leukemia: Where Are We in the Current TKI Era?
Hematology Disease Topics & Pathways:
Diseases, Adult, Therapies, Non-Biological, CML, Mechanisms, Study Population, Myeloid Malignancies, pharmacology, multi-systemic interactions, proteomics
Saturday, December 9, 2017, 7:30 AM-9:00 AM
Bldg C, Lvl 1, Hall C1 (Georgia World Congress Center)
Saturday, December 9, 2017, 2:00 PM-3:30 PM
Bldg B, Lvl 3, B312-B314 (Georgia World Congress Center)

Javid Moslehi, MD

Vanderbilt School of Medicine, Nashville, TN

Disclosures: Moslehi: Novartis: Consultancy; Takeda: Consultancy; Ariad: Consultancy; Acceleron: Consultancy; Pharmacyclics: Consultancy; Daiichi Sankyo: Consultancy; Regeneron: Consultancy; Vertex: Consultancy; Incyte: Consultancy; Rgenix: Consultancy; Bristol-Myers Squibb: Consultancy; Pfizer: Consultancy; Verastem: Consultancy; Heat Biologics: Consultancy; StemCentRx: Consultancy.